Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 02, 2015 1:42 PM ET


Company Overview of EnGeneIC Ltd.

Company Overview

EnGeneIC Ltd., a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company’s drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo. It serves customers in Australia, Singapore, Japan, and India. The company was incorporated in 2000 and is based in Lane Cove West, Australia.

2/25 Sirius Road

Lane Cove West, NSW 2066


Founded in 2000


61 2 9420 5844


61 2 9878 5922

Key Executives for EnGeneIC Ltd.

Co-Managing Director and Director
Founder, Co-Managing Director and Director
Compensation as of Fiscal Year 2015.

EnGeneIC Ltd. Key Developments

EnGeneIC Ltd. Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors

EnGeneIC Ltd. announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia. The Phase 1 Tailored-EDV trial is an open-label feasibility study of a single delivery agent (EGFR)-EDVs packaged with the clinician's chosen therapy in subjects with advanced solid tumors who have no further curative treatment options. Eligible patients with a variety of intractable tumor indications, including triple-negative breast cancer, non-small cell lung cancer and metastatic colorectal cancer, will be dosed intravenously, receiving a combination of (EGFR)-EDVs, chemotherapy and functional nucleic acids, such as siRNA, which may address issues of chemotherapy resistance. The therapeutic payload for each patient will be specifically chosen for his or her individual disease. The first patient dosed is suffering from advanced Adrenal Cell Carcinoma (ACC) and received a siRNA that blocks cell division.

EnGeneIC Ltd. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM

EnGeneIC Ltd. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Himanshu Brahmbhatt, Co-Managing Director and Director, Jennifer A. MacDiarmid, Founder, Co-Managing Director and Director.

EnGeneIC Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:30 AM

EnGeneIC Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Recent Private Companies Transactions

Private Placement
March 12, 2015
Private Placement
December 12, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EnGeneIC Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at